The Bina Farm Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 39 Miller St, Norfolk, MA 02056 Phone: 508-651-2462 |
Ms. Jessica Jean Kemble, BS, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 58 Main St, Norfolk, MA 02056 Phone: 508-954-6800 |
Ms. Margaret Singer, MSOTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2 Timberline Dr, Norfolk, MA 02056 Phone: 508-446-4035 |
Mrs. Lauren Ann Love, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 28 Lafayette Ln, Norfolk, MA 02056 Phone: 508-384-3848 |
Elizabeth C Mitro Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15 Willow Place, Norfolk, MA 02056 Phone: 508-346-3906 |
Mary A Nuhibian, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3 Knoll Dr, Norfolk, MA 02056 Phone: 508-528-5292 |
Jean A Croll, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 52 Noon Hill Ave, Norfolk, MA 02056 Phone: 508-560-4007 Fax: 508-520-4895 |
News Archive
Empowering families with skills, resources and knowledge to improve their lifestyle is the focus of a University of Queensland study into reducing childhood obesity.
New research shows that in a dynamic mind-body interaction during the interpretation of prolonged stress, cells from the immune system are recruited to the brain and promote symptoms of anxiety.
The world's fattest mice can overeat without developing insulin resistance or diabetes thanks to a glut of a key hormone, a dichotomy that helps explain why not all obese people are diabetic, a UT Southwestern Medical Center researcher has found.
A tiny capsule invented at a UCLA lab could go a long way toward improving cancer treatment. Devising a method for more precise and less invasive treatment of cancer tumors, a team led by researchers from the UCLA Henry Samueli School of Engineering and Applied Science has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
› Verified 2 days ago